RNAi and CRISPR/Cas9: Revolutionizing Drug Discovery


In drug discovery, the key to success often depends on the models used. This webinar discusses how Charles River’s model creation partner, Mirimus, has leveraged RNA interference (RNAi) and CRISPR/Cas9 technologies to enhance the speed and precision of new genetically engineered mouse models. This robust system provides a cost-effective, scalable platform for the production of mice with enormous predictive power that will shape development of better-tolerated therapies, pushing drug discovery research into a new era. 


  • Prem K. Premsrirut, MD, PhD, President/CEO, Mirimus, Inc.

Related Resources